Eli Lilly Weight-Loss Drug Zepbound Shows Superior Results to Wegovy in Phase 3 Study
MT Newswires Live
May 12, 2025
Eli Lilly (LLY) said Sunday that its weight-loss drug showed results superior to Novo Nordisk's (NVO) Wegovy in a phase 3 study evaluating the safety and efficacy of the two drugs over 72 weeks in obese or overweight patients with at least one weight-related medical problem and without diabetes.
The company asid Zepbound met its primary endpoint of weight loss, reducing weight by 20.2% or 50.3 pounds compared to 13.7% or 33.1 pounds for Wegovy.
The drug also met all five of its secondary endpoints in the study, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.